{"id":106094,"date":"2026-02-02T08:21:14","date_gmt":"2026-02-02T07:21:14","guid":{"rendered":"https:\/\/www.medipan.de\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\/"},"modified":"2026-02-02T09:35:57","modified_gmt":"2026-02-02T08:35:57","slug":"anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus","status":"publish","type":"post","link":"https:\/\/www.medipan.de\/de\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\/","title":{"rendered":"Anti\u2013Faktor-H-Autoantik\u00f6rper und ELISA-Testung: Optimierung der Diagnostik beim atypischen h\u00e4molytisch-ur\u00e4mischen Syndrom (aHUS)"},"content":{"rendered":"\n<p>Das atypische h\u00e4molytisch-ur\u00e4mische Syndrom (aHUS), auch als komplementvermittelte thrombotische Mikroangiopathie (CM-TMA) bezeichnet, ist eine seltene, jedoch lebensbedrohliche Erkrankung, die durch eine Dysregulation des alternativen Komplementwegs verursacht wird. Unter den bekannten \u00c4tiologien spielen Autoantik\u00f6rper gegen den Komplementfaktor H (Anti-Faktor-H-Autoantik\u00f6rper) eine entscheidende Rolle und sind f\u00fcr etwa 10 % der F\u00e4lle verantwortlich<sup data-fn=\"055e2161-b45b-4fa1-8d02-fcc2ca51f054\" class=\"fn\"><a href=\"#055e2161-b45b-4fa1-8d02-fcc2ca51f054\" id=\"055e2161-b45b-4fa1-8d02-fcc2ca51f054-link\">1<\/a><\/sup>. Der zuverl\u00e4ssige labordiagnostische Nachweis dieser Antik\u00f6rper ist von zentraler Bedeutung, da er unmittelbaren Einfluss auf Diagnosestellung, Prognoseeinsch\u00e4tzung und therapeutische Strategien hat.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"814\" height=\"328\" src=\"https:\/\/www.medipan.de\/wp-content\/uploads\/2026\/02\/aHUS-de-e1770019623209.png\" alt=\"\" class=\"wp-image-106098\" srcset=\"https:\/\/www.medipan.de\/wp-content\/uploads\/2026\/02\/aHUS-de-e1770019623209.png 814w, https:\/\/www.medipan.de\/wp-content\/uploads\/2026\/02\/aHUS-de-e1770019623209-300x121.png 300w, https:\/\/www.medipan.de\/wp-content\/uploads\/2026\/02\/aHUS-de-e1770019623209-768x309.png 768w\" sizes=\"auto, (max-width: 814px) 100vw, 814px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Warum die Testung auf Anti-Faktor-H-Antik\u00f6rper klinisch relevant ist<\/strong><\/h3>\n\n\n\n<p>Patientinnen und Patienten mit Anti-Faktor-H-Antik\u00f6rpern profitieren h\u00e4ufig von gezielten immunsuppressiven Therapien, wie Kortikosteroiden oder Rituximab, zus\u00e4tzlich zum Plasmaaustausch. Eine fr\u00fchzeitige und zuverl\u00e4ssige Identifizierung von Anti-Faktor-H-Immunglobulin G (IgG) ist daher entscheidend, um irreversible Organsch\u00e4den, insbesondere ein Nierenversagen, zu verhindern. Der ELISA-Test gilt als Referenzmethode zum Nachweis und zur Quantifizierung von Anti-Faktor-H-Antik\u00f6rpern in klinischen Laboren.<\/p>\n\n\n\n<p>Die zunehmende Verf\u00fcgbarkeit kommerzieller Testkits wirft jedoch wichtige Fragen hinsichtlich der Vergleichbarkeit der Assays, ihrer Sensitivit\u00e4t, Spezifit\u00e4t und Standardisierung auf.<\/p>\n\n\n\n<p><strong>Vergleich von ELISA-Assays zum Nachweis von Anti-Faktor-H-Autoantik\u00f6rpern<\/strong><\/p>\n\n\n\n<p>Eine k\u00fcrzlich in Kanada durchgef\u00fchrte Studie verglich drei ELISA-Methoden zum Nachweis von Anti-Faktor-H-Antik\u00f6rpern<sup data-fn=\"6c3684b1-1b22-410b-b8f7-38b705cf12a4\" class=\"fn\"><a href=\"#6c3684b1-1b22-410b-b8f7-38b705cf12a4\" id=\"6c3684b1-1b22-410b-b8f7-38b705cf12a4-link\">2<\/a><\/sup>:<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignright size-large is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"694\" src=\"https:\/\/www.medipan.de\/wp-content\/uploads\/2026\/01\/MTP-AdobeStock_226346450-1024x694.jpeg\" alt=\"\" class=\"wp-image-106069\" style=\"width:298px;height:auto\" srcset=\"https:\/\/www.medipan.de\/wp-content\/uploads\/2026\/01\/MTP-AdobeStock_226346450-1024x694.jpeg 1024w, https:\/\/www.medipan.de\/wp-content\/uploads\/2026\/01\/MTP-AdobeStock_226346450-300x203.jpeg 300w, https:\/\/www.medipan.de\/wp-content\/uploads\/2026\/01\/MTP-AdobeStock_226346450-768x521.jpeg 768w, https:\/\/www.medipan.de\/wp-content\/uploads\/2026\/01\/MTP-AdobeStock_226346450-1536x1042.jpeg 1536w, https:\/\/www.medipan.de\/wp-content\/uploads\/2026\/01\/MTP-AdobeStock_226346450-2048x1389.jpeg 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n<\/div>\n\n\n<ul class=\"wp-block-list\">\n<li>einen validierten In-house-ELISA auf Grundlage des Pariser Protokolls,<\/li>\n\n\n\n<li>einen <strong>kommerziellen ELISA der Firma GA Generic Assays <\/strong>sowie<\/li>\n\n\n\n<li>einen zweiten kommerziell verf\u00fcgbaren ELISA-Testkit.<\/li>\n<\/ul>\n\n\n\n<p>Insgesamt wurden 75 Plasmaproben von Patientinnen und Patienten mit Verdacht auf aHUS parallel untersucht. Die Studie bewertete die qualitative \u00dcbereinstimmung, die quantitative Korrelation sowie die analytische Leistungsf\u00e4higkeit unter routinem\u00e4\u00dfigen diagnostischen Bedingungen.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Zentrale Ergebnisse: Sensitivit\u00e4t, Spezifit\u00e4t und \u00dcbereinstimmung<\/strong><\/h3>\n\n\n\n<p>Alle Assays zeigten eine gute Leistungsf\u00e4higkeit bei der Identifizierung negativer Proben. Bei positiven Proben sowie bei der Quantifizierung der Antik\u00f6rper traten jedoch Unterschiede auf:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Der ELISA von <strong>GA Generic Assays zeigte die h\u00f6chste \u00dcbereinstimmung<\/strong> mit der In-house-Referenzmethode. Er wies eine <strong>gute Sensitivit\u00e4t<\/strong> sowie eine starke quantitative Korrelation und Reproduzierbarkeit auf.<\/li>\n\n\n\n<li>Der zweite kommerzielle Assay zeigte eine <strong>gr\u00f6\u00dfere Variabilit\u00e4t<\/strong>, insbesondere bei hohen Antik\u00f6rpertitern, und tendierte dazu, die Konzentrationen von Anti-Faktor-H-Antik\u00f6rpern zu untersch\u00e4tzen.<\/li>\n\n\n\n<li>Die ausschlie\u00dfliche Anwendung der vom Hersteller definierten Cut-off-Werte erh\u00f6hte das Risiko <strong>falsch-negativer Ergebnisse<\/strong>. Dagegen f\u00fchrte eine Anpassung der Positivit\u00e4tsgrenzen anhand laborinterner gesunder Kontrollkollektive (z. B. Mittelwert + 2 Standardabweichungen) zu einer deutlich verbesserten diagnostischen Sensitivit\u00e4t bei nur minimalem Verlust an Spezifit\u00e4t.<\/li>\n<\/ul>\n\n\n\n<p>Diese Ergebnisse best\u00e4tigen, dass <strong>ELISA-Assays<\/strong> zum Nachweis von Anti-Faktor-H-Antik\u00f6rpern nicht ohne Weiteres austauschbar sind, insbesondere im Rahmen des Patientenmonitorings und der longitudinalen Verlaufskontrolle.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Praktische Implikationen f\u00fcr diagnostische Laboratorien<\/strong><\/h3>\n\n\n\n<p>Die Studie hebt mehrere bew\u00e4hrte Vorgehensweisen f\u00fcr Laboratorien hervor, die Anti-Faktor-H-Antik\u00f6rpertestungen durchf\u00fchren:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Verwendung <strong>optimierter Cut-off-Werte<\/strong>, die an die untersuchte Population angepasst sind, wie auch in der Norm ISO 15189 f\u00fcr die Akkreditierung medizinischer Laboratorien empfohlen<sup data-fn=\"d9680c19-c128-43e1-8772-1819f46de217\" class=\"fn\"><a href=\"#d9680c19-c128-43e1-8772-1819f46de217\" id=\"d9680c19-c128-43e1-8772-1819f46de217-link\">3<\/a><\/sup>.<\/li>\n\n\n\n<li>Einbeziehung<strong> individueller Leerwert-\/Blankkontrollen<\/strong> zur Reduktion falsch-positiver Ergebnisse durch unspezifische Bindungen.<\/li>\n\n\n\n<li>Bei klinischer Relevanz <strong>Best\u00e4tigung positiver Befunde durch eine zweite ELISA-Methode<\/strong> zur Absicherung therapeutischer Entscheidungen.<\/li>\n\n\n\n<li>Ber\u00fccksichtigung der Tatsache, dass ELISA-Assays ausschlie\u00dflich <strong>frei zirkulierende Antik\u00f6rper <\/strong>erfassen und somit immunkomplexgebundene Anti-Faktor-H-Antik\u00f6rper potenziell nicht detektiert werden<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Fazit<\/h3>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignright size-large is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"576\" src=\"https:\/\/www.medipan.de\/wp-content\/uploads\/2021\/01\/Niere_AdobeStock_331950373-1024x576.jpeg\" alt=\"This image is a detailed digital illustration of the human abdominal and thoracic organs, rendered in a stylized, glowing X-ray or thermal view. The central focus is on the two prominent, bean-shaped kidneys, which are highlighted in a bright, glowing red. These are located on either side of the spine, below the liver and stomach. The surrounding organs are shown in a translucent blue outline, which includes: The liver and stomach in the upper part of the abdomen. The large and small intestines in the lower part. The lungs and parts of the rib cage are also visible in the upper torso.The overall impression is a visualization of the human anatomy, specifically highlighting the position and structure of the kidneys in relation to other internal organs.\" class=\"wp-image-14905\" style=\"width:315px;height:auto\" srcset=\"https:\/\/www.medipan.de\/wp-content\/uploads\/2021\/01\/Niere_AdobeStock_331950373-1024x576.jpeg 1024w, https:\/\/www.medipan.de\/wp-content\/uploads\/2021\/01\/Niere_AdobeStock_331950373-300x169.jpeg 300w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n<\/div>\n\n\n<p>Der zuverl\u00e4ssige Nachweis von Anti-Faktor-H-Autoantik\u00f6rpern ist f\u00fcr die moderne Diagnostik des atypischen h\u00e4molytisch-ur\u00e4mischen Syndroms (aHUS) von entscheidender Bedeutung. Zwar bieten kommerzielle ELISA-Kits zug\u00e4ngliche und standardisierte L\u00f6sungen, ihre analytische Leistungsf\u00e4higkeit variiert jedoch. Die Evidenz unterst\u00fctzt den Einsatz gut validierter ELISA-Assays, wie beispielsweise <a href=\"https:\/\/www.medipan.de\/de\/products\/4067-anti-faktor-h\/\"><em>Anti-Faktor H<\/em> <\/a>von GA Generic Assays, in Verbindung mit einer sorgf\u00e4ltigen Ergebnisinterpretation und laborindividueller Validierung.<\/p>\n\n\n\n<p>Die Optimierung der ELISA-Testung auf Anti-Faktor-H-Antik\u00f6rper kann zu einer fr\u00fchzeitigeren Diagnosestellung, pr\u00e4ziseren Therapieentscheidungen und verbesserten klinischen Ergebnissen f\u00fcr Patientinnen und Patienten mit aHUS und verwandten Komplementerkrankungen f\u00fchren.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">In der Studie verwendetes Produkt<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><a href=\"https:\/\/www.medipan.de\/de\/products\/4067-anti-faktor-h\/\" target=\"_blank\" rel=\"noreferrer noopener\">4067 \u2013 Anti-Faktor H<\/a><\/td><td>ELISA zum quantitativen Nachweis von IgG-Antik\u00f6rpern gegen den Komplementfaktor H<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<div class=\"wp-block-button has-custom-width wp-block-button__width-50\"><a class=\"wp-block-button__link has-white-color has-blue-dark-background-color has-text-color has-background has-link-color has-medium-font-size has-custom-font-size wp-element-button\" href=\"https:\/\/www.medipan.de\/wp-content\/uploads\/2024\/11\/Flyer-REF-4067Anti-Faktor-Hdeu.pdf\" target=\"_blank\" rel=\"noreferrer noopener\" data-wplink-edit=\"true\">4067 \u2013 Anti-Faktor H Flyer<\/a><\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Literaturverweis<\/h2>\n\n\n<ol class=\"wp-block-footnotes\"><li id=\"055e2161-b45b-4fa1-8d02-fcc2ca51f054\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?sort=date&amp;term=Dragon-Durey+MA&amp;cauthor_id=21051740\" target=\"_blank\" rel=\"noreferrer noopener\">Marie-Agn\u00e8s Dragon-Durey <em>et al.<\/em>, (2010)_Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome<\/a> <a href=\"#055e2161-b45b-4fa1-8d02-fcc2ca51f054-link\" aria-label=\"Zur Fu\u00dfnotenreferenz 1 navigieren\">\u21a9\ufe0e<\/a><\/li><li id=\"6c3684b1-1b22-410b-b8f7-38b705cf12a4\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41310920\/\" target=\"_blank\" rel=\"noreferrer noopener\">Thouzeau-Benghezal <em>et al.<\/em>, (2025)_Comparison of 3 ELISA Assays for the Detection and Quantification of Abs anti-Complement Factor H<\/a> <a href=\"#6c3684b1-1b22-410b-b8f7-38b705cf12a4-link\" aria-label=\"Zur Fu\u00dfnotenreferenz 2 navigieren\">\u21a9\ufe0e<\/a><\/li><li id=\"d9680c19-c128-43e1-8772-1819f46de217\"><a href=\"https:\/\/www.iso.org\/standard\/56115.html\" target=\"_blank\" rel=\"noreferrer noopener\">International Organization for Standardization. ISO 15189:2012 (E) Medical laboratories \u2013 Requirements for quality and competence<\/a> <a href=\"#d9680c19-c128-43e1-8772-1819f46de217-link\" aria-label=\"Zur Fu\u00dfnotenreferenz 3 navigieren\">\u21a9\ufe0e<\/a><\/li><\/ol>\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Das atypische h\u00e4molytisch-ur\u00e4mische Syndrom (aHUS), auch als komplementvermittelte thrombotische Mikroangiopathie (CM-TMA) bezeichnet, ist eine seltene, jedoch lebensbedrohliche Erkrankung, die durch eine Dysregulation des alternativen Komplementwegs verursacht wird. Unter den bekannten \u00c4tiologien spielen Autoantik\u00f6rper gegen den Komplementfaktor H (Anti-Faktor-H-Autoantik\u00f6rper) eine entscheidende Rolle und sind f\u00fcr etwa 10 % der F\u00e4lle verantwortlich. Der zuverl\u00e4ssige labordiagnostische Nachweis dieser [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":9099,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"[{\"content\":\"<a href=\\\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?sort=date&amp;term=Dragon-Durey+MA&amp;cauthor_id=21051740\\\" target=\\\"_blank\\\" rel=\\\"noreferrer noopener\\\">Marie-Agn\u00e8s Dragon-Durey <em>et al.<\/em>, (2010)_Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome<\/a>\",\"id\":\"055e2161-b45b-4fa1-8d02-fcc2ca51f054\"},{\"content\":\"<a href=\\\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41310920\/\\\" target=\\\"_blank\\\" rel=\\\"noreferrer noopener\\\">Thouzeau-Benghezal <em>et al.<\/em>, (2025)_Comparison of 3 ELISA Assays for the Detection and Quantification of Abs anti-Complement Factor H<\/a>\",\"id\":\"6c3684b1-1b22-410b-b8f7-38b705cf12a4\"},{\"content\":\"<a href=\\\"https:\/\/www.iso.org\/standard\/56115.html\\\" target=\\\"_blank\\\" rel=\\\"noreferrer noopener\\\">International Organization for Standardization. ISO 15189:2012 (E) Medical laboratories \u2013 Requirements for quality and competence<\/a>\",\"id\":\"d9680c19-c128-43e1-8772-1819f46de217\"}]"},"categories":[177],"tags":[],"class_list":["post-106094","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-products-news-de"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Anti\u2013Factor H Antibodies ELISA: A Key Diagnostic Tool in aHUS<\/title>\n<meta name=\"description\" content=\"Accurate anti\u2013factor H antibodies ELISA is key for diagnosing atypical hemolytic uremic syndrome (aHUS). A comparison of Three ELISA Assays.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.medipan.de\/de\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anti\u2013Factor H Antibodies ELISA: A Key Diagnostic Tool in aHUS\" \/>\n<meta property=\"og:description\" content=\"Accurate anti\u2013factor H antibodies ELISA is key for diagnosing atypical hemolytic uremic syndrome (aHUS). A comparison of Three ELISA Assays.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.medipan.de\/de\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\/\" \/>\n<meta property=\"og:site_name\" content=\"Medipan &amp; GA Generic Assays\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/people\/Medipan-GA-Generic-Assays\/pfbid02ULuoTqAH3VaVSiKK1yK6und3uDLDWT5sPtqVXyQHcW1QBfBX1ywC47X62DBGZgril\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-02T07:21:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-02T08:35:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.medipan.de\/wp-content\/uploads\/2023\/10\/MTP-Labrorant_AdobeStock_299915758-1-scaled.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dr. Stefano Frasca\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Stefano Frasca\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"4\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\\\/\"},\"author\":{\"name\":\"Dr. Stefano Frasca\",\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/#\\\/schema\\\/person\\\/79bd5fbc4d559d6bf0daa2d30d420904\"},\"headline\":\"Anti\u2013Faktor-H-Autoantik\u00f6rper und ELISA-Testung: Optimierung der Diagnostik beim atypischen h\u00e4molytisch-ur\u00e4mischen Syndrom (aHUS)\",\"datePublished\":\"2026-02-02T07:21:14+00:00\",\"dateModified\":\"2026-02-02T08:35:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\\\/\"},\"wordCount\":636,\"publisher\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.medipan.de\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/MTP-Labrorant_AdobeStock_299915758-1-scaled.jpeg\",\"articleSection\":[\"Produktneuigkeiten\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\\\/\",\"url\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\\\/\",\"name\":\"Anti\u2013Factor H Antibodies ELISA: A Key Diagnostic Tool in aHUS\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.medipan.de\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/MTP-Labrorant_AdobeStock_299915758-1-scaled.jpeg\",\"datePublished\":\"2026-02-02T07:21:14+00:00\",\"dateModified\":\"2026-02-02T08:35:57+00:00\",\"description\":\"Accurate anti\u2013factor H antibodies ELISA is key for diagnosing atypical hemolytic uremic syndrome (aHUS). A comparison of Three ELISA Assays.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.medipan.de\\\/de\\\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.medipan.de\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/MTP-Labrorant_AdobeStock_299915758-1-scaled.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.medipan.de\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/MTP-Labrorant_AdobeStock_299915758-1-scaled.jpeg\",\"width\":2560,\"height\":1707,\"caption\":\"Scientist in lab holding a 96 well plate with biological samples for analysis \\\/ Biologist pipetting samples in micro plate in the laboratory\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anti\u2013Faktor-H-Autoantik\u00f6rper und ELISA-Testung: Optimierung der Diagnostik beim atypischen h\u00e4molytisch-ur\u00e4mischen Syndrom (aHUS)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/#website\",\"url\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/\",\"name\":\"Medipan.de\",\"description\":\"Your reliable partner in autoimmune diagnostics\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/#organization\",\"name\":\"Medipan GmbH & GA Generic Assays GmbH\",\"url\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.medipan.de\\\/wp-content\\\/uploads\\\/2021\\\/01\\\/logo_transparent.png\",\"contentUrl\":\"https:\\\/\\\/www.medipan.de\\\/wp-content\\\/uploads\\\/2021\\\/01\\\/logo_transparent.png\",\"width\":108,\"height\":49,\"caption\":\"Medipan GmbH & GA Generic Assays GmbH\"},\"image\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/people\\\/Medipan-GA-Generic-Assays\\\/pfbid02ULuoTqAH3VaVSiKK1yK6und3uDLDWT5sPtqVXyQHcW1QBfBX1ywC47X62DBGZgril\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/medipan-generic-assays-gmbh\\\/?originalSubdomain=de\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCFTKVg_v7n57CG7i9rPv-NQ\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/#\\\/schema\\\/person\\\/79bd5fbc4d559d6bf0daa2d30d420904\",\"name\":\"Dr. Stefano Frasca\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d0184820b8afa2a8d194b02b85fb7b9f6430623d6e8f2b5deabba7d3c67bc75f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d0184820b8afa2a8d194b02b85fb7b9f6430623d6e8f2b5deabba7d3c67bc75f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d0184820b8afa2a8d194b02b85fb7b9f6430623d6e8f2b5deabba7d3c67bc75f?s=96&d=mm&r=g\",\"caption\":\"Dr. Stefano Frasca\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anti\u2013Factor H Antibodies ELISA: A Key Diagnostic Tool in aHUS","description":"Accurate anti\u2013factor H antibodies ELISA is key for diagnosing atypical hemolytic uremic syndrome (aHUS). A comparison of Three ELISA Assays.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.medipan.de\/de\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\/","og_locale":"de_DE","og_type":"article","og_title":"Anti\u2013Factor H Antibodies ELISA: A Key Diagnostic Tool in aHUS","og_description":"Accurate anti\u2013factor H antibodies ELISA is key for diagnosing atypical hemolytic uremic syndrome (aHUS). A comparison of Three ELISA Assays.","og_url":"https:\/\/www.medipan.de\/de\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\/","og_site_name":"Medipan &amp; GA Generic Assays","article_publisher":"https:\/\/www.facebook.com\/people\/Medipan-GA-Generic-Assays\/pfbid02ULuoTqAH3VaVSiKK1yK6und3uDLDWT5sPtqVXyQHcW1QBfBX1ywC47X62DBGZgril\/","article_published_time":"2026-02-02T07:21:14+00:00","article_modified_time":"2026-02-02T08:35:57+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/www.medipan.de\/wp-content\/uploads\/2023\/10\/MTP-Labrorant_AdobeStock_299915758-1-scaled.jpeg","type":"image\/jpeg"}],"author":"Dr. Stefano Frasca","twitter_card":"summary_large_image","twitter_misc":{"Verfasst von":"Dr. Stefano Frasca","Gesch\u00e4tzte Lesezeit":"4\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.medipan.de\/de\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\/#article","isPartOf":{"@id":"https:\/\/www.medipan.de\/de\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\/"},"author":{"name":"Dr. Stefano Frasca","@id":"https:\/\/www.medipan.de\/de\/#\/schema\/person\/79bd5fbc4d559d6bf0daa2d30d420904"},"headline":"Anti\u2013Faktor-H-Autoantik\u00f6rper und ELISA-Testung: Optimierung der Diagnostik beim atypischen h\u00e4molytisch-ur\u00e4mischen Syndrom (aHUS)","datePublished":"2026-02-02T07:21:14+00:00","dateModified":"2026-02-02T08:35:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.medipan.de\/de\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\/"},"wordCount":636,"publisher":{"@id":"https:\/\/www.medipan.de\/de\/#organization"},"image":{"@id":"https:\/\/www.medipan.de\/de\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\/#primaryimage"},"thumbnailUrl":"https:\/\/www.medipan.de\/wp-content\/uploads\/2023\/10\/MTP-Labrorant_AdobeStock_299915758-1-scaled.jpeg","articleSection":["Produktneuigkeiten"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.medipan.de\/de\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\/","url":"https:\/\/www.medipan.de\/de\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\/","name":"Anti\u2013Factor H Antibodies ELISA: A Key Diagnostic Tool in aHUS","isPartOf":{"@id":"https:\/\/www.medipan.de\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.medipan.de\/de\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\/#primaryimage"},"image":{"@id":"https:\/\/www.medipan.de\/de\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\/#primaryimage"},"thumbnailUrl":"https:\/\/www.medipan.de\/wp-content\/uploads\/2023\/10\/MTP-Labrorant_AdobeStock_299915758-1-scaled.jpeg","datePublished":"2026-02-02T07:21:14+00:00","dateModified":"2026-02-02T08:35:57+00:00","description":"Accurate anti\u2013factor H antibodies ELISA is key for diagnosing atypical hemolytic uremic syndrome (aHUS). A comparison of Three ELISA Assays.","breadcrumb":{"@id":"https:\/\/www.medipan.de\/de\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.medipan.de\/de\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.medipan.de\/de\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\/#primaryimage","url":"https:\/\/www.medipan.de\/wp-content\/uploads\/2023\/10\/MTP-Labrorant_AdobeStock_299915758-1-scaled.jpeg","contentUrl":"https:\/\/www.medipan.de\/wp-content\/uploads\/2023\/10\/MTP-Labrorant_AdobeStock_299915758-1-scaled.jpeg","width":2560,"height":1707,"caption":"Scientist in lab holding a 96 well plate with biological samples for analysis \/ Biologist pipetting samples in micro plate in the laboratory"},{"@type":"BreadcrumbList","@id":"https:\/\/www.medipan.de\/de\/anti-factor-h-autoantibodies-and-elisa-testing-optimizing-diagnosis-in-atypical-hemolytic-uremic-syndrome-ahus\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.medipan.de\/de\/"},{"@type":"ListItem","position":2,"name":"Anti\u2013Faktor-H-Autoantik\u00f6rper und ELISA-Testung: Optimierung der Diagnostik beim atypischen h\u00e4molytisch-ur\u00e4mischen Syndrom (aHUS)"}]},{"@type":"WebSite","@id":"https:\/\/www.medipan.de\/de\/#website","url":"https:\/\/www.medipan.de\/de\/","name":"Medipan.de","description":"Your reliable partner in autoimmune diagnostics","publisher":{"@id":"https:\/\/www.medipan.de\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.medipan.de\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/www.medipan.de\/de\/#organization","name":"Medipan GmbH & GA Generic Assays GmbH","url":"https:\/\/www.medipan.de\/de\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.medipan.de\/de\/#\/schema\/logo\/image\/","url":"https:\/\/www.medipan.de\/wp-content\/uploads\/2021\/01\/logo_transparent.png","contentUrl":"https:\/\/www.medipan.de\/wp-content\/uploads\/2021\/01\/logo_transparent.png","width":108,"height":49,"caption":"Medipan GmbH & GA Generic Assays GmbH"},"image":{"@id":"https:\/\/www.medipan.de\/de\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/people\/Medipan-GA-Generic-Assays\/pfbid02ULuoTqAH3VaVSiKK1yK6und3uDLDWT5sPtqVXyQHcW1QBfBX1ywC47X62DBGZgril\/","https:\/\/www.linkedin.com\/company\/medipan-generic-assays-gmbh\/?originalSubdomain=de","https:\/\/www.youtube.com\/channel\/UCFTKVg_v7n57CG7i9rPv-NQ"]},{"@type":"Person","@id":"https:\/\/www.medipan.de\/de\/#\/schema\/person\/79bd5fbc4d559d6bf0daa2d30d420904","name":"Dr. Stefano Frasca","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/d0184820b8afa2a8d194b02b85fb7b9f6430623d6e8f2b5deabba7d3c67bc75f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d0184820b8afa2a8d194b02b85fb7b9f6430623d6e8f2b5deabba7d3c67bc75f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d0184820b8afa2a8d194b02b85fb7b9f6430623d6e8f2b5deabba7d3c67bc75f?s=96&d=mm&r=g","caption":"Dr. Stefano Frasca"}}]}},"_links":{"self":[{"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/posts\/106094","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/comments?post=106094"}],"version-history":[{"count":4,"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/posts\/106094\/revisions"}],"predecessor-version":[{"id":106105,"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/posts\/106094\/revisions\/106105"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/media\/9099"}],"wp:attachment":[{"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/media?parent=106094"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/categories?post=106094"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/tags?post=106094"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}